Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor

Autor: Oh Woong Kwon, Da Ru Chi Moon, Soon Hyun Kim, Yong Sung You, Dong Kyu Lee
Rok vydání: 2015
Předmět:
Male
Vascular Endothelial Growth Factor A
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
Retinal Neovascularization
chemistry.chemical_compound
Polypoidal choroidal vasculopathy
Medicine
Aflibercept
General Medicine
Bevacizumab
Vascular endothelial growth factor
Treatment Outcome
medicine.anatomical_structure
Intravitreal Injections
Drug Therapy
Combination
Female
Original Article
medicine.symptom
Tomography
Optical Coherence
medicine.drug
medicine.medical_specialty
Recombinant Fusion Proteins
Refractory
Ranibizumab
Ophthalmology
Humans
Anti-vascular endothelial growth factor
Retrospective Studies
Dose-Response Relationship
Drug
Choroid
business.industry
Macular degeneration
Choroid Diseases
medicine.disease
eye diseases
Surgery
Receptors
Vascular Endothelial Growth Factor
chemistry
Wet Macular Degeneration
sense organs
business
Follow-Up Studies
Zdroj: Korean Journal of Ophthalmology : KJO
ISSN: 2092-9382
1011-8942
DOI: 10.3341/kjo.2015.29.4.226
Popis: Purpose: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). Methods: This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated. Results: BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 μm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 μm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 μm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV. Conclusions: Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy.
Databáze: OpenAIRE
Externí odkaz: